← Back to Search

Treatment for Prostate Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Luke Nordquist, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within one week of 64cu-sar-bispsma pet/ct imaging
Awards & highlights

Study Summary

This trial is testing a new drug that could help find prostate cancer lesions in men.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within one week of 64cu-sar-bispsma pet/ct imaging
This trial's timeline: 3 weeks for screening, Varies for treatment, and within one week of 64cu-sar-bispsma pet/ct imaging for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess safety of 64Cu-SAR-bisPSMA (all patients).
Secondary outcome measures
Clinical Management plan before vs after 64Cu-SAR-bisPSMA PET/CT Imaging.
Disease Staging adjustment (for patients with known disease at entry) before vs after 64Cu-SAR-bisPSMA PET/CT Imaging.
Disease status adjustment (patients with suspected disease at entry) before vs after 64Cu-SAR-bisPSMA PET/CT Imaging.
Other outcome measures
Disease detection ability of 64Cu-SAR-bisPSMA PET (all patients).

Find a Location

Who is running the clinical trial?

Luke Nordquist, MDLead Sponsor
Clarity PharmaceuticalsUNKNOWN

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT05286840 — Phase 1 & 2
Prostate Cancer Research Study Groups:
Prostate Cancer Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT05286840 — Phase 1 & 2
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT05286840 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment still open for this research endeavor?

"According to the clinicaltrials.gov database, this medical trial is not currently enrolling patients; it was initially posted on March 28th 2022 and last updated on March 9th 2022. Although enrollment has closed for this study, there are 1,320 other trials that are actively recruiting right now."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer
Luke Nordquist, MD 2022. "64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05286840.
~50 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top